Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
about
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.Polydatin Protects Diabetic Heart against Ischemia-Reperfusion Injury via Notch1/Hes1-Mediated Activation of Pten/Akt Signaling.
P2860
Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@ast
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@en
type
label
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@ast
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@en
prefLabel
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@ast
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@en
P2093
P2860
P1476
Polydatin ameliorates lipid an ...... ubtilisin/kexin type 9 (PCSK9)
@en
P2093
Cheng Chen
Heqing Huang
Jiantao Ye
Junying Huang
Peiqing Liu
P2860
P2888
P356
10.1186/S12933-015-0325-X
P407
P577
2016-02-01T00:00:00Z
P5875
P6179
1029154920